Prevention and management of transplant-associated diabetes

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 17, 2011, Pages 2641-2655

  Jenssen, Trond ^a,b   Hartmann, Anders ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Calcineurin inhibitors; Diabetes mellitus; Glucocorticoids; Hypoglycemic agents; Immunosuppressive drugs; Insulin; MTor inhibitors; Transplantation

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EVEROLIMUS; GLUCOCORTICOID; GLUCOSE; HEMOGLOBIN A1C; IMMUNOSUPPRESSIVE AGENT; INCRETIN; INSULIN; LOW DENSITY LIPOPROTEIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESSENGER RNA; METFORMIN; METFORMIN PLUS REPAGLINIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL ANTIDIABETIC AGENT; PREDNISOLONE; RAPAMYCIN; SULFONYLUREA; TACROLIMUS; TRANSCRIPTION FACTOR NFAT; TRIACYLGLYCEROL; UNINDEXED DRUG; VILDAGLIPTIN;

ACUTE GRAFT REJECTION; ACUTE KIDNEY FAILURE; ALGORITHM; ANTIHYPERTENSIVE THERAPY; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CONTINUOUS INFUSION; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIABETOGENESIS; DISEASE SEVERITY; DRUG CHOICE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GLYCEMIC INDEX; GRAFT FAILURE; HEPATITIS C VIRUS; HEREDITY; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; MONOTHERAPY; NEPHROTOXICITY; NEW ONSET DIABETES AFTER TRANSPLANTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; ORTHOSTATIC HYPOTENSION; OUTPATIENT CARE; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; REVIEW; RNA TRANSLATION; SEPTICEMIA; SIDE EFFECT; SMOKING CESSATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ANIMALS; DIABETES MELLITUS; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; RISK FACTORS;

EID: 81255195240     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.628936     Document Type: Review

References (110)

1. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. World Health Organization; 1999
2. Davidson J, Wilkinson A, Dantal J, et al. New-Onset Diabetes after Transplantation: 2003 international consensus guidelines. Transplantation 2003;75(Suppl):SS3-SS24
3. Wilkinson A, Davidson J, Dotta F, et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 2005;19:291-8
4. Cosio FG, Kudva Y, van der Velde M, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005;67:2415-21
5. Valderhaug TG, Hjelmesæth J, Hartmann A, et al. The association of early post-transplant glucose levels with long-term mortality. Diabetologia 2011;54:1341-9
6. Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003;3:178-85
7. Hjelmesæth J, Hartmann A, Leivestad T, et al. The impact of early-diagnosed newonset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006;69:588-95
8. Cole EH, Johnston O, Rose CL, et al. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol 2008;3:814-21
9. Matas AJ, Wilkinson A, Dantal J, et al. Posttransplant diabetes mellitus and acute rejection: Impact on kidney transplant outcome. Transplantation 2008;85:338-43
10. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2011;34(Suppl 1):S62-9
11. Selvaraj N, Boddy Z, Sridhar MG. Increased glycation of hemoglobin in chronic renal failure: (Corrected) potential role of oxidative stress. Arch Med Res 2008;39:277-84; published erratum appears in Arch Med Res 2008;39:466
12. De Marchi S, Cecchin E, Basile A, et al. More on the increase of hemoglobin A1c in chronic renal failure: the role of acidosis. Nephron 1983;35:49-53
13. Hornum M, Jørgensen KA, Hansen JM, et al. New-onset diabetes mellitus after kidney transplantation in Denmark. Clin Am J Soc Nephrol 2010;5:709-16
14. Hagen M, Hjelmesæth J, Jenssen T, et al. A 6-year prospective study on new onset diabetes mellitus, insulin release and insulin sensitivity in renal transplant patients. Nephrol Dial Transplant 2003;18:2154-9
15. Montori VM, Velosa JA, Basu A, et al. Post-transplant diabetes: a systematic review of the literature. Diabetes Care 2002;25:583-92
16. Baid S, Cosimi AB, Farrell ML, et al. Post-transplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001;72:1066-72
17. Knobler H, Stagnaro-Green A, Wallenstein S, et al. Higher incidence of diabetes in liver transplant recipients with hepatitis C. J Clin Gastroenterol 1998;26:30-3
18. Hjelmesæth J, Hartmann A, Kofstad J, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997;64:979-83
19. Valderhaug TG, Hjelmeæsth J, Rollag H, et al. Reduced incidence of new-onset posttransplantation diabetes mellitus during the last decade. Transplantation 2007;84:1125-30
20. Cosio FG, Pesavento TE, Osei K, et al. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 2001;59:732-7
21. Hertz MI, Taylor DO, Trulock EP, et al. The registry of the International Society for Heart and Lung Transplantation: nineteenth official report. J Heart Lung Transplant 2002;21:950-70
22. Silverborn M, Jeppsson A, Martensson G, Nilsson F. New-onset cardiovascular risk factors in lung transplant recipients. J Heart Lung Transplant 2005;24:1536-43
23. Soule JL, Olyaei AJ, Boslaugh TA, et al. Hepatitis C infection increases the risk of new-onset diabetes after transplantation in liver allograft recipients. Am J Surg 2005;189:552-7
24. Ducluox D, Kazory A, Chalopin JM. Posttransplant diabetes mellitus and atherosclerotic events in renal transplant recipients: a prospective study. Transplantation 2005;79:438-43
25. Kuo HT, Sampaio MS, Vincenti F, et al. Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: An analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (PPTN/UNOS) database. Am J Kidney Dis 2010;56:1127-39
26. Hjelmesæth J, Hagen M, Hartmann A, et al. The impact of impaired insulin release and insulin resistance on glucose intolerance after renal transplantation. Clin Transplant 2002;16:389-96
27. Hjelmesæth J, Jenssen T, Midtvedt K, et al. Insulin resistance after renal transplantation. Impact of immunosuppressive and antihypertensive therapy. Diabetes Care 2001;24:2121-6
28. Hur KY, Nam CM, Kim MS, et al. Risk factors associated with the onset and progression of posttransplantation diabetes in renal allograft recipients. Diabetes Care 2007;30:609-15
29. Khalili M, Lim JW, Bass N, et al. New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl 2004;10:349-55
30. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007;7:1506-14
31. Driscoll C, Cashion A, Hathaway DK, et al. Posttransplant diabetes mellitus in liver transplant recipients. Prog Transplant 2006;16:110-16
32. Martinez-Dolz L, Almenar L, Martinez-Ortis L, et al. Predictive factors for development of diabetes mellitus post-heart transplant. Transplant Proc 2005;37:4064-6
33. Depczynski B, Daly B, Campbell LV, et al. Predicting the occurrence of diabetes mellitus in recipients of heart transplants. Diabet Med 2000;17:15-19
34. Saliba F, Lakehal M, Pageaux GP, et al. Risk factor for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection: an observational multicenter study. Liver Transpl 2007;13:136-44
35. Fabrizi F, Martin P, Dixit V, et al. Post-transplant diabetes mellitus and HCV sero-positive status after renal transplantation: Meta-analysis of clinical studies. Am J Transplant 2005;5:2433-40
36. Hjelmesæth J, Muller F, Jenssen T, et al. Asymptomatic cytomegalus virus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 2004;47:1550-6
37. Aasebø W, Midtvedt K, Valderhaug TG, et al. Impaired glucose homeostasis in renal transplant recipients receiving basiliximab. Nephrol Dial Transplant 2010;25:1289-93
38. Andrews RC, Walker BR.Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci 1999;96:513-23
39. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96:23-43
40. Lambillotte C, Gilon P, Henquin JC. Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J Clin Invest 1997;99:414-23
41. Delaunay F, Khan A, Cintra A, et al. Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. J Clin Invest 1997;100:2094-8
42. Burroughs TE, Lentine KL, Takemoto SK, et al. Influence of early posttransplantation prednisone and calcineurin inhibitor dosages on the incidence of new-onset diabetes. Clin J Am Soc Nephrol 2007;2:517-23
43. Pascual J, Galeano C, Royuela A, Zamora J. A systematic review on steroid withdrawal between 3 and 6 months after kidney transplantation. Transplantation 2010;90:343-9
44. Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A metaanalysis. Transplantation 2010;89:1-14
45. Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008;248:564-77
46. Luan FL, Steffick DE, Ojo AO. New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. Transplantation 2011;91:334-41
47. Midtvedt K, Hjelmesæth J, Hartmann A, et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J Am Soc Nephrol 2004;15:3233-9
48. Vitko S, Klinger M, Salmela K, et al. Two cortico-steroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study. Transplantation 2005;80:1734-41
49. Bergrem HA, Bergrem H, Hartmann A, et al. Role of prednisolone pharmacokinetics in postchallenge glycemia after renal transplantation. Ther Drug Monit 2008;30:583-90
50. Laftavi MR, Staphan R, Stefanick B, et al. Randomized prospective trial of early steroid withdrawal compared with low-dose steroids in renal transplant recipients using serial protocol biopsies to assess efficacy and safety. Surgery 2005;137:364-71
51. Stillman IE, English J, Burdmann EA, et al. Prednisone alters the histopathology of chronic cyclosporine nephropathy. Exp Nephrol 1997;5:61-8
52. Weir MR, Fink JC. Risk for posttransplant diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 1999;31:1-13
53. Van Duijnhoven AM, Christiaans MHL, Boots HMM, et al. Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression. J Am Soc Nephrol 2002;13:213-20
54. Margreiter R; for the European Tacrolimus vs. Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosorin microemulsion in renal transplantation: a randomized multicentre study. Lancet 2002;359:741-6
55. Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclosporin as primary immunousppression for kidney transplant recipients: meta-analysis and meta-regression of randomized trials. BMJ 2005;331:810-21
56. Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004;4:583-95
57. Marks WH, Harding MW, Hanschumacher R, et al. The immunochemical distribution of cyclophilin in normal mammalian tissues. Transplantation 1991;52:340-5
58. Tamura K, Fujimura T, Tsutsumi T, et al. Transcitional inhibition of insulin by FK506 and possible involvement ofFK506 binding protein-12 in pancreatic beta-cell. Transplantation 1995;59:1606-13
59. Øzbay LA, Smidt K, Mortensen DM, et al. Cyclosporin and tacrolimus impair insulin secretion and transcriptional reglation in INS-1E beta-cells. Br J Pharmacol 2011;162:136-46
60. Redmon JB, Olson LK, Armstrong MB, et al. Effects of Tacrolimus [FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest 1996;98:2786-93
61. Boots JMM, van Duijnhoven EM, Christiaans MHL, et al. Glucose metabolism in renal transplant receipients on tacrolimus: The effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 2002;13:221-7
62. Dumortier J, Bernard S, Bouffard Y, Biollo O. Conversion from tacrolimus to cyclosporine in liver transplanted patients with diabetes mellitus. Liver Transpl 2006;12:659-64
63. Bloom RD, Rao V, Weng F, et al. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 2002;13:1374-80
64. Midtvedt K, Jenssen T, Hatmann A, et al. No change in insulin sensitivity in renal transplant recipients converted from standard to once-daily prolonged release tacrolimus. Nephrol Dial Transplant 2011. [Epub ahead of print]
65. Asberg A, Midtvedt K, Line PD, et al. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. Transplantation 2006;82:62-8
66. Di Paolo S, Teutonico A, Leogrande D, et al. Chronic inhibition of mammalian target of rapamycin signaling down-regulates insulin receptor substrates 1 and 2 and AKT activiation: a crossroad between cancer and diabetes? J Am Soc Nephrol 2006;17:2236-44
67. Fraenkel M, Ketzinel-Gilad M, Ariav Y, et al. mTor inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 2008;57:945-57
68. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000;69:1252-60
69. MacDonald AS; The Rapamune global study group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for the prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001;71:271-80
70. Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: Effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005;16:3128-35
71. Romagnoli J, Citterio F, Nanni G, et al. Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine. Transplant Proc 2006;38:1034-6
72. Morrisett JD, Abdel-Fattah G, Hoogeveen R, et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 2002;43:1170-80
73. Johnston O, Rose CL, Webster AC, Gill JC. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008;19:1411-18
74. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50
75. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
76. Mari A, Tura A, Natali A, et al. Impaired beta cell glucose sensitivity rather than inadequate compensation for insulin resistance is the dominant defect in glucose intolerance. Diabetologia 2010;53:749-56
77. Bergrem H, Gretland Valderhaug T, Hartmann A, et al. Undiagnosed diabetes in kidney transplant candidates: a case-finding study. Clin J Am Soc Nephrol 2010;5:616-22
78. Zelle DM, Corpeleijn E, Stolk RP. Low physical activity and risk of cardiovascular and all-cause mortality in renal transplant recipients. Clin J Am Soc Nephrol 2011;6:898-905
79. Valderhaug TG, Jenssen T, Hartmann A, et al. Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetes mellitus after renal transplantation. Transplantation 2009;88:429-34
80. Zerr KJ, Furnary AP, Grunkenmeier GL, et al. Glucose control lowers the risk of wound infection in diabetics after open heart operations. Ann Thorac Surg 1997;63:356-61
81. Furnary AP, Gao G, Grunkenmeier GL, et al. Continuous insulin infusion reduces mortality in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 2003;125:1007-21
82. Van Den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006;354:449-61
83. Clement S, Braithwaite SS, Magee MF, et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care 2004;27:553-91 Erratum in Diabetes Care 2004;27856. Diabetes Care 2004;27:1255
84. Qseem A, Humphrey LL, Chou R, et al. Use of intensive insulin therapy for the management of glycemic control in hospitalized patients: A clinical practice guideline from the American College of Physicians. Ann Intern Med 2011;154:260-7
85. Nathan DM, Buse JB, Davdidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 2009;52:17-30
86. Nathan DM, Cleary PA, Backlund JY, et al. Intensive treatment and cardiovascular disease in patients withtype 1 diabetes. N Engl J Med 2005;353:2643-53
87. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
88. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011;34:S11-61
89. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effect of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
90. KDIGO. Clinical Practice Guideline for the Care of Kidney Transplant Recipients. Am J Transplant 2009;9(Suppl 3):S66-80
91. Identification number: NCT01304836 Available from: www.clinicaltrials.gov 92. Kurian B, Joshi R, Helmuth A. Effectiveness and long-term safety of thiazolidinediones and metformin in renal transplant recipients. Endocr Pract 2008;14:979-84
92. Shaw JS, Wilmot RL, Kilpatrick ES. Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet Med 2007;24:1160-3
93. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes [UKPDS 33). Lancet 1998;352:837-53
94. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med 2008;25:145-54
95. Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010;363:1410-18
96. Sagedal S, Asberg A, Hartmann A, et al. Glipizide treatment of posttransplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients. Clin Transplant 1998;12:553-6
97. Turk TR, Pietruck F, Dolff S, et al. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am J Transplant 2006;6:842-6
98. Voytovich MH, Haukereid C, Hjelmesaeth J, et al. Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients. Clin Transplant 2007;21:246-51
99. Kajosaari LI, Niewmi M, Neuvonen M, et al. Cyclosporine markedly raises the plasma concentration of repaglinide. Clin Pharmacol Ther 2005;78:388-99
100. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
101. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-35
102. Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes. Diabetes Care 2008;31:845-51
103. Luther P, Baldwin D Jr. Pioglitazone in the management of diabetes mellitus after transplantation. Am J Transplant 2004;4:2135-8
104. Voytovich MH, Simonsen C, Jenssen T, et al. Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients. Nephrol Dial Transplant 2005;20:413-18
105. Pinelli NR, Moore CL, Tomasello S. Incretin-based therapy in chronic kidney disease. Adv Chronic Kidney Dis 2010;17:439-49
106. Pirelli NR, Nemerovski CW, Koelling TM. Successful long-term use of sitagliptin for the treatment of new-onset diabetes mellitus after solid organ transplantation: a case report. Transplant Proc 2011;43:2113-15
107. Haidinger M, Werzowa J, Voigt HC, et al. A randomized, placebo-controlled, double-blind trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation. Trials 2010;11:91
108. Identification number: NCT00740363 Available from: www.clinicaltrials.gov
109. Chan JC, Scott R, Ariona Ferreira JC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008;10:545-55
110. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003;361:2024-31